Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia

International Journal of Clinical Practice

Volumn 53, Issue 8, 1999, Pages 609-611

  Wierzbicki, A S ^a   Lumb, P J ^a   Chik, G ^a   Crook, M A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; CROSS-OVER STUDIES; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; SIMVASTATIN;

EID: 0033395629     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Simon Broome Register Group. Mortality in treated heterozygous familial hypercholesterolemia: implications for clinical management. Atherosclerosis 1999; 142: 105-112.
2. Wierzbicki AS, Lumb PJ, Cheung J, Crook MA. Experience with simvastatin-fenofibrate combination therapy compared to simvastatin-cholestyramine therapy for familial hypercholesterolemia. Q J Med 1997; 90: 631-634.
3. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. High-dose atorvastatin therapy compared with traditional therapeutic regimes in severe heterozygous familial hypercholesterolemia. Q J Med 1998; 91: 291-294.
4. Wierzbicki AS, Lumb PJ, Semra YK et al. Efficacy of atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidemias. Q J Med 1999; 92: 387-394.
5. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscl Thromb Vasc Biol 1995; 15: 678-682.
6. Black DM. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In: Jacotot B, Mathe D, Frucharty J-C, Eds. Atherosclerosis X. Amsterdam: Elsevier, 1995; 307-310.
7. Jones PJ, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin , pravastatin, lovastatin and fluvastatin patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998: 81: 582-587.
8. Davidson MH, Stein EA, Dujovne CA et al. The efficacy and safety and six week tolerability of simvastatin 80 and 160mg/day. Am J Cardiol 1997; 79: 38-42.
9. Crouse JR, Frohlich J. Ose L et al. Effects of high dose of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 1999; 82: 1476-1477.
10. Bakker-Arkema R, Davidson MH, Goldstein RJ et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996; 275: 128-133.
11. Stein EA, Lane M, Laskarzewski P. Comparison of statins in hyper-triglyceridemia. Am J Cardiol 1998; 81: 66B-69B.
12. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins. JAMA 1998; 279: 1643-1650.
13. Saloma V, Rasi V, Pekannen J et al. Hemostatic risk factors and prevalent coronary heart disease: the FINRISK hemostasis study. Eur Heart J 1994; 15: 1293-1299.
14. Maresca G, Di Blasio A. Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 1368-1377.
15. Jerling JC, Vorster HH, Oosthuizen W, Vermakk WJH. Effects of simvastatin, a 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitor, on the hemostatic balance of familial hypercholesterolemic subjects. Fibrinol Proteol 1997; 11: 91-96.
16. Marais AD, Firth JC, Bateman ME et al. Atorvaslatin: an effective agent in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17: 1527-1532.
17. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effects of atorvastatin on plasma fibrinogen. Lancet 1998; 351: 591-592.
18. Nair DR, Papadakis JA, Jagroop IA et al. Statins and fibrinogen. Lancet 1998; 351: 1430.
19. Bertolotto A, Bandinelli S, Ruocco L et al. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolemia. Atherosclerosis 1999; 143: 455-457.